Sharoon Qaiser — University of Kentucky

Education/Academic qualification

Post Doctoral Fellow, University Of Cincinnati

2020

Residency, University Of Kentucky

2019

Residency, University Of Kentucky

2016

Doctor of Medicine, King Edward Medical College

2005

2 Finished
7 Active

19379A: Long-term, Open-label (dose-blinded), Extension study of Eptinezumab in Children and Adolescents with Chronic or Episodic Migraine
Qaiser, S.
H. Lundbeck A/S
5/12/23 → 5/12/25
Project: Research project
19357A: Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intravenous (IV) Eptinezumab in Paediatric Patients (6 to 17 years) for the Preventive Treatment of Episodic Migraine
Qaiser, S.
H. Lundbeck A/S
5/12/23 → 5/12/25
Project: Research project
REBUILD-1- I5Q-MC-CGAS(g): A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age with Episodic Migraine # the REBUILD-1 Study
Qaiser, S.
Eli Lilly and Company
3/17/22 → 3/17/25
Project: Research project
REBUILD-2 - I5Q-MC-CGAT( e): A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adolescent Patients 12 to 17 Years of Age with Chronic Migraine - the REBUILD-2 Study
Qaiser, S.
Eli Lilly and Company
3/16/22 → 7/9/25
Project: Research project
PIONEER-PEDS2-H8H-MC-LAHW(b): A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients with Migraine
Qaiser, S.
Eli Lilly and Company
3/2/22 → 1/24/25
Project: Research project